Advanced search
Publication Cover
COPD: Journal of Chronic Obstructive Pulmonary Disease Volume 18, 2021 - Issue 1
Submit an article Journal homepage
2,058
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Adherence to GOLD Recommendations among Swiss Pulmonologists and General Practitioners

Joana Louise Marmya University Clinic of Medicine, Cantonal Hospital Baselland, Liestal, Switzerland;b Faculty of Medicine, University of Basel, Basel, SwitzerlandView further author information
,
Jens Peter Diedrichc Boehringer Ingelheim GmbH, Basel, SwitzerlandView further author information
,
Cordula Cadusa University Clinic of Medicine, Cantonal Hospital Baselland, Liestal, SwitzerlandView further author information
,
Peter Grendelmeiera University Clinic of Medicine, Cantonal Hospital Baselland, Liestal, Switzerland;b Faculty of Medicine, University of Basel, Basel, SwitzerlandView further author information
,
Anne Tschachera University Clinic of Medicine, Cantonal Hospital Baselland, Liestal, SwitzerlandView further author information
,
Thomas Dieterlea University Clinic of Medicine, Cantonal Hospital Baselland, Liestal, Switzerland;b Faculty of Medicine, University of Basel, Basel, SwitzerlandView further author information
,
Prashant N. Chhajeda University Clinic of Medicine, Cantonal Hospital Baselland, Liestal, Switzerland;b Faculty of Medicine, University of Basel, Basel, SwitzerlandView further author information
&
Jörg Daniel Leuppia University Clinic of Medicine, Cantonal Hospital Baselland, Liestal, Switzerland;b Faculty of Medicine, University of Basel, Basel, SwitzerlandCorrespondence[email protected]
View further author information
 show all
Pages 9-15 | Received 06 May 2020, Accepted 29 Nov 2020, Published online: 21 Dec 2020

Figures & data

Table 1. Patients’ baseline characteristics.

Table 2. Previous use of symptom assessment tools.

Figure 1. Baseline pharmacological treatment according to GOLD 2017 category. LAMA, monotherapy with LAMA; LABA, monotherapy with LABA; LAMA/LABA, fixed or free combinations of LAMA and LABA; LAMA/LABA/ICS, any triple combinations; ICS (+ other), ICS-containing regimens other than triple combinations (LAMA/LABA/ICS); other, regimens without ICS, LAMA, and LABA. Missing data are not shown.

Figure 1. Baseline pharmacological treatment according to GOLD 2017 category. LAMA, monotherapy with LAMA; LABA, monotherapy with LABA; LAMA/LABA, fixed or free combinations of LAMA and LABA; LAMA/LABA/ICS, any triple combinations; ICS (+ other), ICS-containing regimens other than triple combinations (LAMA/LABA/ICS); other, regimens without ICS, LAMA, and LABA. Missing data are not shown.

Table 3. Actual treatment adjustments versus adjustments required according to GOLD 2017 recommendations.

Figure 2. Reasons for treatment adjustments decided by GPs (n = 102) and PULs (n = 155). Multiple choices were possible.

Figure 2. Reasons for treatment adjustments decided by GPs (n = 102) and PULs (n = 155). Multiple choices were possible.

Figure 3. Reasons for choosing a LAMA/LABA combination (in patients who are prescribed LAMA or LABA) by GPs (n = 140) and PUL (n = 212). Multiple choices were possible.

Figure 3. Reasons for choosing a LAMA/LABA combination (in patients who are prescribed LAMA or LABA) by GPs (n = 140) and PUL (n = 212). Multiple choices were possible.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.